Jan 17, 2023
Ad hoc announcement pursuant to Art. 53 LR Inhaled murepavadin shown to be well tolerated at all dose levels Program derived
INHALED ANTIBIOTIC FOR PSEUDOMONAS IN CF SHOWS SAFETY IN EARLY TRIAL
A novel inhaled antibiotic called iMPV, developed by biotech company Spexis to treat Pseudomonas aeruginosa infections, showed a promising safety profile in a first trial conducted in healthy volunteers.
The therapy contains the antibiotic murepavadin and is designed to be inhaled through the mouth. It has shown efficacy against P. aeruginosa strains that are resistant to many other commonly used antibiotics.